Over-the-counter products exist in a different regulatory category with minimal oversight, making direct comparison impossible from a scientific standpoint
billed via G0108/G0109 Smoking cessation: Critical smoking dramatically accelerates all DM macrovascular and microvascular complications Pharmacologic Targets (ADA 2026) A1C target: 20): Finerenone (non-steroidal MRA), SGLT-2 inhibitors per ADA 2026 updated CKD recommendations Monitoring Technologies Continuous glucose monitoring (CGM): ADA 2026 Recommendation 13.5 recommended for all Type 1 DM
Pancreatitis risk remains low with both medications (0.10.2% reported incidence), though patients with personal or family history of pancreatic disease warrant careful screening before starting either therapy
Stop and talk to a dermatologist
Levothyroxine, while treating hypothyroidism, can indirectly influence blood sugar levels
One theoretical concern: aggressive caloric restriction accompanying drug-induced satiety reduction could suppress gonadotropins in women with low body fat reserves
